|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||171.84 - 172.98|
|52-week range||133.65 - 173.65|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||25.89|
|Earnings date||19 Oct 2021|
|Forward dividend & yield||4.24 (2.46%)|
|Ex-dividend date||23 Aug 2021|
|1y target est||187.39|
Moderna (NASDAQ: MRNA), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) share the U.S. COVID-19 vaccine market right now. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how Novavax (NASDAQ: NVAX) could potentially shake up the COVID vaccine market.
In fact, the three companies I'll discuss today are in the top 50 of investing app Robinhood's most popular user holdings. Johnson & Johnson (NYSE: JNJ) will never again grow as quickly as Dogecoin, but it won't collapse as suddenly, either. The key reason that Johnson & Johnson is better than Dogecoin is that the company actually makes things -- specifically, a plethora of consumer healthcare and pharmaceutical products that people need on a daily basis to survive.
Moderna (NASDAQ: MRNA) is now officially a member of the S&P 500. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Moderna's tenure on the S&P 500 index will be short-lived. Let's go over to Moderna, which is now officially, I think today, a member of the S&P 500 Index.